Purdue Pharma L.P. to Present Data from Research Studies at PAINWeek® 2016 Annual Conference

STAMFORD, Conn.--()--Purdue Pharma L.P. will present results from nine clinical and non-clinical research studies as well as host two satellite events during the 10th Annual PAINWeek® Conference, taking place Sept. 6-10, 2016 in Las Vegas.

Purdue Pharma will present the following posters, including one oral presentation at the conference. Jaren Howard, PharmD, BCPS, Associate Director, Medical Affairs Strategic Research will present, "The economic burden of opioid abuse and its drivers: evidence from a payer perspective" during the poster podium presentations on Fri, Sept. 9 from 7 - 7:55 a.m. PDT at The Cosmopolitan on level 3, room Gracia 5.

The posters will be available for viewing beginning Wed., Sept. 7, at 3 p.m. PDT. Authors will be available at the Scientific Session reception on Thurs., Sept. 8 from 6:30 – 8:30 p.m. PDT. The abstracts may be accessed online here.

                 
TITLE       AUTHORS       POSTER #

“An Evaluation of the FDA-Recommended Abuse Potential
Questions in Chronic Pain Patients Without a History of
Recreational Opioid Use”

     

Palsgrove AC, Cole JC, Trivedi B,
Alfieri T, Mayne T

      4

“Analysis of Pre-Screening Data from Pediatric Pain
Trials”

      Baldridge S, Wallace L, Folta T       12

“Changes in Nonmedical Use of OxyContin After
Reformulation With Abuse Deterrent Properties (Encore)”

     

DeVeaugh-Geiss A, Coplan P,
Chilcoat H, Sessler N, Singh R

      32

“Impact of abuse-deterrent properties of Hysingla ER on
rates of abuse and diversion monitoring internet postings”

     

DeVeaugh-Geiss A, Chilcoat H,
Coplan P, Harikrishnan V,
Besharat A, Green J

      33

“The Long-term Analgesic Effectiveness of Opioid Therapy in
Chronic Non-Cancer Pain Patients: A Literature Review of
Randomized Controlled, Open-label, and Epidemiologic
Studies”

     

Gudin J, Nalamachu S, Wallace
L, Matsuno R, Coplan P

      49

“The Costs and Cost Drivers of Opioid Misuse by Diagnosis:
Abuse, Dependence, and Overdose/Poisoning”

     

Howard J, Kirson NY, Scarpati
LM, Dincer AP, Hanway J,
Zichlin M,Birnbaum HG

      59

“The Economic Burden of Opioid Abuse and Its Drivers:
Evidence From a Payer Perspective”

     

Howard J, Kirson NY, Scarpati
LM, Dincer AP, Hanway J,
Zichlin M,Birnbaum HG

      60
“Buprenorphine Transdermal System (Butrans) Utilization”       Wallace L, Kadakia A       134

“Are Immediate-Release (IR) Opioids Really Safer Than
Extended-Release (ER) Opioids?: A Case Study Using Data on
ER and IR Oxycodone (Encore)”

     

Wallace L, Coplan P, DeVeaugh-
Geiss A, Kadakia A

      135
           

In addition, Purdue Pharma will also sponsor two educational, satellite presentations:

                         
Title       Speakers       Date & Time       Location

Guidelines, Practice, and Policy:
Separating the Myths from the Facts
with OADP”

 

     

J. David Haddox,
DDS, MD, Vice
President, Health
Policy, Purdue
Pharma L.P.

 

Ellen Battista, DNS,
ANP, PNP, Pain
Treatment
Consultants of
Western New York

      Tues, Sept. 6, 2016

12:30 – 1:30 p.m. PDT

     

The Cosmopolitan

Level 3

Brera Ballroom

Purdue Pharma L.P. Extended-
Release Opioid Product Portfolio
Options

     

Charles E. Argoff,
MD, Albany, NY

 

Michael J. Brennan,
MD, Fairfield, CT

      Fri, Sept. 9, 2016

8 – 8:50 a.m. PDT

     

The Cosmopolitan

Level 3

Brera Ballroom

                 

The PAINWeek exhibit hall will be open from Wed. to Fri., Sept. 7 to 9. You will find the Purdue Pharma representatives in the following locations:

Exhibit hours may be accessed here: http://www.painweek.org/attendees/exhibit-hall.html

A map of the PAINWeek Exhibit Hall floor plan may be accessed here: http://www.painweek.org/assets/documents/general/pw_16_fp-7-11-16.pdf

Purdue Pharma is proud to sponsor the following PAINWeek special events:

  • Advanced Practice Provider Day - Thurs, Sept. 8
  • Opioid Awareness Day - Fri, Sept. 9
  • Exhibit Hall Closing Reception - Fri, Sept. 9 from 3:30 - 4:30 p.m. PDT
 

WARNING: ADDICTION, ABUSE AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION

 

Addiction, Abuse, and Misuse

OXYCONTIN® exposes patients and other users to the risks of opioid addiction, abuse and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing OXYCONTIN and monitor all patients regularly for the development of these behaviors or conditions [see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of OXYCONTIN. Monitor for respiratory depression, especially during initiation of OXYCONTIN or following a dose increase. Instruct patients to swallow OXYCONTIN tablets whole; crushing, chewing, or dissolving OXYCONTIN tablets can cause rapid release and absorption of a potentially fatal dose of oxycodone [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of OXYCONTIN, especially by children, can result in a fatal overdose of oxycodone [see Warnings and Precautions (5.2)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of OXYCONTIN during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.3)].

Cytochrome P450 3A4 Interaction

The concomitant use of OXYCONTIN with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving OXYCONTIN and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.14) and Clinical Pharmacology (12.3)].

 
 

Full prescribing information for OxyContin® (oxycodone HCl) extended-release tablets, including Boxed Warning, is available at http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o.

 

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4 INTERACTION

 

Addiction, Abuse, and Misuse

HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing HYSINGLA ER, and monitor all patients regularly for the development of these behaviors or conditions [see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER. Monitor for respiratory depression, especially during initiation of HYSINGLA ER or following a dose increase. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.2)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.3)].

Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.11), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].

 
 

Full prescribing information for Hysingla® ER (hydrocodone bitartrate) extended-release tablets, including Boxed Warning, is available at http://app.purduepharma.com/xmlpublishing/pi.aspx?id=h.

 

WARNING: ADDICTION, ABUSE, and MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; and NEONATAL OPIOID WITHDRAWAL SYNDROME

Addiction, Abuse, and Misuse

BUTRANS® exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing BUTRANS, and monitor all patients regularly for the development of these behaviors or conditions [see Warnings and Precautions (5.1) and Overdosage (10)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of BUTRANS. Monitor for respiratory depression, especially during initiation of BUTRANS or following a dose increase. Misuse or abuse of BUTRANS by chewing, swallowing, snorting or injecting buprenorphine extracted from the transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death [see Warnings and Precautions (5.2)].

Accidental Exposure

Accidental exposure to even one dose of BUTRANS, especially by children, can result in a fatal overdose of buprenorphine [see Warnings and Precautions (5.2)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of BUTRANS during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.3)].

 
 

Full prescribing information for BUTRANS® (buprenorphine) Transdermal System, including Boxed Warning, is available at http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b.

About PAINWeek®

PAINWeek is the largest U.S. pain conference for frontline practitioners with an interest in pain management. Convening at The Cosmopolitan of Las Vegas for its 10th year on Sept. 6-10, 2016, PAINWeek expects to welcome more than 2,300 physicians, nurses, pharmacists, and other healthcare professionals for a comprehensive program of course offerings, satellite events, and exhibits. Over 120 hours of continuing medical education activities will be presented. To learn more and register for PAINWeek 2016, visit www.painweek.org.

About Purdue Pharma L.P.

Purdue Pharma is a privately-held pharmaceutical company and is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The company’s leadership and employees are committed to serving healthcare professionals, patients and caregivers quality products and educational resources to support their proper use. Purdue Pharma is engaged in the research, development, production and distribution of both prescription and over-the-counter medicines and hospital products. With Purdue Pharma’s expertise in drug development, commercialization, and life-cycle management, the company is diversifying in high-need areas to expand through strategic acquisitions and creative partnerships. For more information please visit www.purduepharma.com or follow the company on Twitter, Instagram, LinkedIn and YouTube.

Contacts

Purdue Pharma L.P.
Catherine London, 203-588-7530
Mobile: 917-763-2709
Corporate Communications
catherine.london@pharma.com

Release Summary

Purdue Pharma L.P. will present results from nine clinical and non-clinical research studies as well as host two satellite events during the 10th Annual PAINWeek® Conference, Sept. 6-10, 2016.

#Hashtags

Contacts

Purdue Pharma L.P.
Catherine London, 203-588-7530
Mobile: 917-763-2709
Corporate Communications
catherine.london@pharma.com